Generalized AChR-Ab+ Myasthenia Gravis: Next Step When Rituximab Has Not Achieved Minimal Manifestation Status
Clinical Scenario
Patients with generalized myasthenia gravis who are antibody-positive for acetylcholine receptor antibodies (AChR-Ab+) and whose disease has remained severe and refractory despite prior immunotherapy.
Previous Treatment Did Not Meet Target
Rituximab was trialled for refractory disease but failed to reach the required goal of minimal manifestation (MM) status or better. This protocol defines the escalation step taken when that target is not achieved.
Treatment Approach (Partial Overview)
The protocol specifies eculizumab for severe, refractory AChR-Ab+ generalized MG. Mandatory pre-treatment steps are required before initiation. The complete sequence, requirements, and clinical management details are available in the full structured regimen.
Treatment Goals
At least a 2-point reduction in the QMG score; achievement of minimal manifestation (MM) status or pharmacologic remission.
References
DOI: 10.1212/WNL.0000000000011124
- Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG.
- Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals.
- In a phase II crossover RCT of 14 patients with refractory generalized AChR-Ab+ MG, at the end of the first treatment period, 6/7 (86%) of eculizumab-treated patients achieved the primary end point of a 2-point reduction in the QMG score, compared to 57% with placebo.
- In addition, 56% (65/116) of patients achieved MM status or pharmacologic remission.
View source ↗